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OBJECTIVES: The aim of this study was to investigate a role of cytochrome P450 20 
(CYP) and peroxidase in ellipticine oxidative activation in two mouse strains differing 21 
in expression of NADPH:CYP reductase (POR) [the HRN (Hepatic Cytochrome P450 22 
Reductase Null) mice, in which POR is deleted in hepatocytes and its wild-type (WT) 23 
  
 
 
counterpart], and in levels of CYP1A1/2 and cytochrome b5 that were modulated by 24 
treatment of these mouse models with a CYP1A inducer, benzo[a]pyrene (BaP).  25 
METHODS: Ellipticine-DNA adducts were detected by 32P-postlabeling. HPLC was 26 
employed for the separation and characterization of ellipticine metabolites.  27 
RESULTS: Hepatic microsomes of HRN and WT mice activate ellipticine to form 28 
ellipticine-derived DNA adducts. A 2.2- and 10.4-fold increase in amounts of 29 
ellipticine-derived DNA adducts formed by liver microsomes was caused by exposure 30 
of HRN and WT mice to BaP, respectively. The results found and utilization of 31 
NADPH and arachidonic acid, cofactors of CYP- and cyclooxygenase (COX)-32 
dependent enzyme systems, respectively, as well as inhibitors of CYP1A1/2 and 3A, 33 
demonstrate that the CYP1A and 3A enzymes play a major role in ellipticine 34 
activation in liver microsomes. In addition, the COX enzyme is important in ellipticine 35 
activation in liver of HRN mice.  36 
CONCLUSION: The CYP1A and 3A enzymes activate ellipticine mainly in liver of WT 37 
mice, whereas peroxidase COX plays this role in liver of HRN mice. Treatment of mice 38 
with BaP increases an impact of CYP1A on ellipticine activation. A pattern of 39 
expression levels of these enzymes plays a crucial role in their impact on this process. 40 
 41 
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Abbreviations:  46 
AHR – aryl hydrocarbon receptor 47 
  
 
 
α-NF – α-naphthoflavone  48 
BaP – benzo[a]pyrene  49 
BPDE – BaP-7,8-dihydrodiol-9,10-epoxide 50 
COX– cyclooxygenase  51 
CYP – cytochrome P450 52 
dG-N2-BPDE – 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo-53 
[a]pyrene 54 
DMSO – dimethyl sulfoxide 55 
EROD – ethoxyresorufin O-deethylase 56 
GAPDH - glyceraldehyde phosphate dehydrogenase  57 
HPLC – high performance liquid chromatography 58 
HRN – Hepatic Cytochrome P450 Reductase Nul 59 
i.p. - intraperitoneally  60 
mEH – microsomal epoxide hydrolase 61 
NADPH – nicotinamidadeninedinucleotide phosphate (reduced) 62 
POR – NADPH:cytochrome P450 reductase 63 
RAL – relative adduct labeling 64 
r. t. – retention time 65 
S.D. – standard deviation 66 
SDS-PAGE – sodium dodecyl sulfate-polyacrylamide gel electrophoresis 67 
TLC – thin-layer chromatography 68 
UV – ultraviolet 69 
WT – wild-type 70 
 71 
  
 
 
INTRODUCTION 72 
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, Fig. 1) and its derivatives are 73 
efficient anticancer compounds that function through multiple mechanisms 74 
participating in cell cycle arrest and initiation of apoptosis [for a summary see 75 
(Auclair, 1987; Garbett & Graves, 2004; Stiborova et al. 2001, 2006c, 2011; Kizek et 76 
al. 2012)]. Ellipticine was found (i) to arrest cell cycle progression due to modulation 77 
of levels of cyclinB1 and Cdc2, and phosphorylation of Cdc2 in human mammary 78 
adenocarcinoma MCF-7 cells, (ii) to initiate apoptosis due to formation of toxic free 79 
radicals, stimulation of the Fas/Fas ligand system and modulation of proteins of Bcl-2 80 
family in several tumor cell lines, (iii) to induce an increase in wild-type p53 and the 81 
rescue of mutant p53 activity, and (iv) to initiate the mitochondria-dependent 82 
apoptotic processes [for a summary see (Kuo et al. 2005a,b; 2006; Stiborova et al. 83 
2011; Kizek et al. 2012)]. Ellipticine also activates the p53 pathway in glioblastoma 84 
cells; its impact on these cancer cells depends on the p53 status. In a U87MG 85 
glioblastoma cell line expressing p53wt, ellipticine provoked an early G0/G1 cell cycle 86 
arrest, whereas in a U373 cell line expressing p53mt it caused arrest in S and G2/M 87 
phase (Martinkova et al. 2010).  88 
The predominant molecular mechanisms of ellipticine’s biological effects were 89 
suggested to be (i) intercalation into DNA and (ii) inhibition of topoisomerase II 90 
(Auclair, 1987; Garbett & Graves, 2004; Stiborova et al. 2011). We also showed that 91 
this antitumor agent forms covalent DNA adducts after its enzymatic activation with 92 
cytochromes P450 (CYP) and peroxidases (Stiborova et al. 2001, 2004, 2006a, 93 
2007a,b, 2008, 2010, 2011, 2012b,c,d; Kotrbova et al. 2011; Kizek et al. 2012), 94 
suggesting an additional DNA-damaging effect of ellipticine.  95 
  
 
 
Of the CYP enzymes investigated, human CYP3A4, followed by CYP1A1 and 96 
1A2 are the most active enzymes oxidizing ellipticine to 12-hydroxy- and 13-97 
hydroxyellipticine, the reactive metabolites that dissociate to ellipticine-12-ylium and 98 
ellipticine-13-ylium which bind to DNA (Stiborova et al. 2004, 2007a, 2011, 2012b,d). 99 
The CYP1A isoforms also efficiently form the other ellipticine metabolites, 7-hydroxy- 100 
and 9-hydroxyellipticine, which are the detoxification products (Fig. 1). Recently we 101 
have found that cytochrome b5 alters the ratio of ellipticine metabolites formed by 102 
CYP1A1, 1A2 and 3A4. While the amounts of the detoxification metabolites (7-103 
hydroxy- and 9-hydroxyellipticine) were either decreased or not changed with added 104 
cytochrome b5, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N2-oxide increased 105 
considerably. The change in amounts of metabolites resulted in an increased 106 
formation of covalent ellipticine-DNA adducts, one of the DNA-damaging 107 
mechanisms of ellipticine antitumor action (Kotrbova et al. 2011; Stiborova et al. 108 
2012b). In addition, we found that levels of the DNA adduct formed by 13-109 
hydroxyellipticine also increased if this ellipticine metabolite was conjugated with 110 
sulfate or acetate by human sulfotransferases 1A1, 1A2, 1A3 and 2A1, or N,O-111 
acetyltransferases 1 and 2 (Moserova et al. 2008; Kotrbova et al. 2011; Stiborova et 112 
al. 2012b) (Fig. 1). Of the mammalian peroxidases, human cyclooxygenase (COX)-2, 113 
ovine COX-1, bovine lactoperoxidase and human myeloperoxidase efficiently 114 
generated ellipticine-derived DNA adducts (Poljakova et al. 2006, Stiborova et al. 115 
2007a). 116 
The same ellipticine-derived DNA adducts that were found in in vitro incubations 117 
of ellipticine with DNA and enzymes activating this drug, were generated also in vivo, 118 
in several tissues of mice and rats exposed to ellipticine. In both animal models, 119 
  
 
 
ellipticine-DNA adduct formation was mediated mainly by CYP1A and 3A enzymes, 120 
but a role of peroxidases in several organs was also proved (Stiborova et al. 2003a, 121 
2003b, 2007b, 2008, 2010). The ellipticine-DNA adducts were also found in several 122 
cancer cell lines expressing CYP and/or peroxidase enzymes and in DNA of rat 123 
mammary adenocarcinoma in vivo (Borek-Dohalska et al. 2004; Poljakova et al. 124 
2007, 2009, 2011, 2013; Martinkova et al. 2009; Stiborova et al. 2011).  125 
All these results indicate that expression levels of CYP and peroxidase 126 
enzymes metabolizing ellipticine seem to be crucial for antitumor, cytostatic and 127 
genotoxic activities of this drug in individual tissues. However, the actual impacts of 128 
these enzymes in vivo depend on several additional factors (Stiborova et al. 2008, 129 
2011). One of them might be the presence of various patterns of individual CYPs and 130 
peroxidases and/or even the presence of other proteins influencing their activities 131 
such as cytochrome b5 in target and non-target tissues (Stiborova et al. 2008, 2011, 132 
2012b; Kotrbova et al. 2011; Kizek et al. 2012).  133 
Therefore, in this study we have used two mouse strains, in which four different 134 
patterns of CYP1A1, 1A2, POR and cytochrome b5, the enzymes that are crucial to 135 
dictate ellipticine metabolism, were expressed. Namely, beside the HRN (Hepatic 136 
Cytochrome P450 Reductase Null) mouse strain, in which NADPH:CYP reductase 137 
(POR), the unique electron donor to CYPs is deleted specifically in hepatocytes, 138 
resulting in the loss of most hepatic CYP function (Henderson et al. 2003; Arlt et al. 139 
2008; Stiborova et al. 2008) and its wild-type (WT) counterpart, we have also utilized 140 
these mouse strains in which the levels of CYP1A1/2 enzymes and cytochrome b5 141 
protein were modulated by their treatment with a strong CYP1A1/2 inducer, 142 
benzo[a]pyrene (BaP) (Arlt et al. 2008, 2012; Hodek et al. 2011; Phillips & Venitt, 143 
  
 
 
2012). The use of such animal models can shed more light on the impact of these 144 
biotransformation enzymes on metabolic activation and/or detoxification of ellipticine 145 
in organisms.   146 
The electrochemical method of Western blotting was used to estimate 147 
cytochrome b5, CYP1A1/2 and POR protein expression in hepatic microsomes of 148 
used mouse models, whereas formation of ellipticine-derived DNA adducts or 149 
ellipticine oxidative metabolites catalyzed by these microsomes were analyzed by the 150 
32P-postlabeling or HPLC methods, respectively (Stiborova et al. 2001, 2006a,c, 151 
2011).  152 
 153 
MATERIAL AND METHODS 154 
Animal treatment 155 
Mouse model strains used in this study were identical to those used in our previous 156 
works (Arlt et al. 2008, 2012). All experiments were approved by, and conducted in 157 
accordance with, the National Institute of Health standards for the care and use of 158 
experimental animals and the University of Cincinnati Medical Center Institutional 159 
Animal Care and Use Committee. HRN (Porlox/lox + CreALB) mice on a C57BL/6 160 
background (CXR Bioscience Ltd., Dundee, UK) used in this study were derived as 161 
described previously (Henderson et al. 2003). Mice homozygous for loxP sites at the 162 
Por locus (Porlox/lox) were used as wild-type (WT). BaP was dissolved in corn-oil at a 163 
concentration of 12.5 mg/ml. Groups of female HRN and WT mice (3 months old, 25-164 
30 g) were treated intraperitoneally (i.p.) with 125 mg/kg body weight (n=3) of BaP 165 
daily either for 1 day (group I) or 5 days. Control mice (n=3) received corn-oil only 166 
either for 1 day or for 5 days. Animals were sacrificed 24 hours after the last dose 167 
  
 
 
(Arlt et al. 2008, 2012). Mouse livers were removed, snap frozen and stored at −80ºC 168 
until analysis. 169 
Preparation of hepatic microsomes 170 
Hepatic microsomes from HRN and WT mice, untreated or treated with BaP as 171 
described above, were isolated as described previously (Stiborova et al. 2011, 172 
2012a; 2012b). Pooled microsomal fractions were used for further analyses.  173 
Preparation of CYP1A1 and POR antibodies  174 
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of 175 
Escherichia coli transfected with a modified CYP1A1 cDNA (Stiborova et al. 2002). 176 
Rabbit liver POR was purified as described (Arlt et al. 2003). Leghorn chickens were 177 
immunized subcutaneously three times (with one week interval) with rat recombinant 178 
CYP1A1 and rabbit hepatic POR antigens (0.1 mg/animal) emulsified in complete 179 
Freund’s adjuvant for the first injection and in incomplete adjuvant for boosters. 180 
Immunoglobulin fraction was purified from pooled egg yolks using fractionation by 181 
polyethylene glycol 6000 (Stiborova et al. 2002; Hodek et al. 2013).  182 
Determination of CYP1A1/2, POR and cytochrome b5 protein levels in hepatic 183 
microsomes 184 
Immunoquantitation of hepatic microsomal CYP1A1, CYP1A2 and POR was done 185 
essentially as described previously using sodium dodecyl sulfate-polyacrylamide gel 186 
electrophoresis (SDS-PAGE) (Stiborova et al., 2002, 2006b; Arlt et al. 2008). CYP 187 
and POR were probed with the chicken anti-rat CYP1A1 and chicken anti-rabbit POR 188 
polyclonal antibodies as reported (Stiborova et al. 2002, 2006b; Arlt et al. 2008). The 189 
antibody against rat recombinant CYP1A1 recognizes both CYP1A1 and CYP1A2 in 190 
mouse liver microsomes. Rat recombinant CYP1A1 and CYP1A2 (in SupersomesTM, 191 
  
 
 
Gentest Corp., USA) and rabbit POR were used as positive controls to identify 192 
protein bands in microsomal samples. Western blot analysis was also used to 193 
determine expression of cytochrome b5; 75 µg microsomal protein was subjected to 194 
SDS-PAGE using 15% gel. After migration, proteins were transferred onto 195 
polyvinylidene difluoride membranes. Cytochrome b5 protein was probed with rabbit 196 
polyclonal anti-cytochrome b5 antibody (1:750; ab69801; Abcam, MA, USA) overnight 197 
at 4°C. Glyceraldehyde phosphate dehydrogenase (GAPDH; 1:750; Millipore, MA, 198 
USA) was used as loading control. The antigen-antibody complex was visualized with 199 
an alkaline phosphatase-conjugated goat anti-rabbit IgG antibody and 5-bromo-4-200 
chloro-3-indolylphosphate/nitrobluetetrazolium as chromogenic substrate (Stiborova 201 
et al. 2002, 2006b; Arlt et al. 2008, 2012). The detection limit was 0.005 pmol 202 
CYP1A1 per lane (Stiborova et al. 2002, 2006b; Arlt et al. 2008) and 0.01 pmol for 203 
the other enzymes and cytochrome b5. 204 
Determination of CYP1A and POR enzymatic activity in hepatic microsomes 205 
The hepatic microsomal samples were characterized for CYP1A activity using 7-206 
ethoxyresorufin O-deetylation (EROD) (Stiborova et al. 2002, 2006b; Arlt et al. 2008). 207 
The activity of POR was measured as reported previously (Arlt et al. 2003).  208 
Microsomal incubations 209 
Incubation mixtures used to generate DNA adduct formation by ellipticine in vitro 210 
consisted of 50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, pooled 211 
hepatic microsomal fraction (n=3) (0.5 mg protein) from either untreated (control) 212 
HRN or WT mice or those treated with BaP (see above), 0.1 mM ellipticine (dissolved 213 
in 7.5 µl methanol) and 0.5 mg of calf thymus DNA in a final volume of 750 µl. 214 
Incubations were also carried out in the presence of a COX cofactor, arachidonic acid 215 
  
 
 
(Eling et al. 1992; Stiborova et al. 2005). Mixtures then contained 0.1 mM arachidonic 216 
acid as cofactor instead of NADPH, and additionally 5 mM magnesium chloride. 217 
Incubations were carried out at 37 ºC for 30 minutes; ellipticine-DNA adduct 218 
formation was found to be linear up to 30 min of incubation (Stiborova et al. 2001). 219 
Control incubations were carried out (i) without microsomes, (ii) without NADPH or 220 
arachidonic acid, (iii) without DNA and (iv) without ellipticine. After the incubation, 221 
DNA was isolated by a standard phenol-chloroform extraction method.  222 
Incubation mixtures used to form the ellipticine metabolites contained 50 mM 223 
potassium phosphate buffer (pH 7.4), 1 mM NADP+, 10 mM D-glucose 6-phosphate, 224 
1 U/ml D-glucose 6-phosphate dehydrogenase (NADPH-generation system), 0.2 mg 225 
protein of pooled hepatic microsomal fraction and 10 µM ellipticine (dissolved in 5 µl 226 
methanol) in a final volume of 500 µl. The reaction was initiated by adding the 227 
substrate. In the control incubation, ellipticine was omitted from the incubation 228 
mixture. After incubation in open glass tubes (37 ºC, 20 min) the reaction was 229 
stopped by adding 100 µl of 2 M NaOH. The oxidation of ellipticine is linear up to 30 230 
min of incubation (Stiborova et al. 2006a). After incubation, 5 µl of 1 mM phenacetine 231 
in methanol was added as an internal standard and the ellipticine metabolites were 232 
extracted twice with ethyl acetate (2 x 1 ml). Analyses of ellipticine metabolites were 233 
performed by HPLC as described (Stiborova et al. 2004, 2006a). Recoveries of 234 
ellipticine metabolites were around 95% in the presence of microsomes without a 235 
CYP cofactor (NADPH-generation system).  236 
DNA adduct detection by 32P-postlabeling analysis 237 
  
 
 
DNA adducts formed by ellipticine were determined by 32P-postlabeling analysis 238 
using the nuclease P1 enrichment version and DNA adducts were resolved by thin-239 
layer chromatography (TLC) (Stiborova et al. 2003a, 2004, 2007a). After 240 
chromatography, TLC sheets were scanned using a Packard Instant Imager (Dowers 241 
Grove, USA) and DNA adduct levels (RAL, relative adduct labeling) were calculated 242 
as described (Stiborova et al. 2003a, 2004, 2007a). Results were expressed as DNA 243 
adducts/108 nucleotides. 244 
Inhibition studies 245 
The following chemicals were used to inhibit the activation of ellipticine to form DNA 246 
adducts in the presence of mouse hepatic microsomes: α-naphtoflavone (α-NF), 247 
which inhibits CYP1A1 and 1A2, ketoconazole, an inhibitor of CYP3A (Rendic & 248 
DiCarlo, 1997; Arlt et al. 2004; Stiborova et al. 2005), and α-lipoic acid, which inhibits 249 
POR (Slepneva et al. 1995). Inhibitors were dissolved in 7.5 µl of methanol, to yield 250 
final concentrations of 0.1 mM in the incubation mixtures. Mixtures were then 251 
incubated at 37 ºC for 10 min with NADPH prior to adding ellipticine, and then 252 
incubated for a further 30 min at 37 ºC. After the incubation, DNA was isolated as 253 
described above. 254 
Statistical analyses 255 
For statistical data analysis we used Student’s t-test. All P-values are two-tailed and 256 
considered significant at the 0.05 level.  257 
 258 
RESULTS AND DISCUSSION 259 
Expression of hepatic CYP1A1, 1A2, POR and cytochrome b5 in HRN and WT mice 260 
is induced by BaP 261 
  
 
 
Hepatic microsomes isolated from both control (untreated) mice and mice treated 262 
with BaP were used in experiments evaluating their efficacies to activate ellipticine to 263 
species forming ellipticine-derived DNA adducts and/or to detoxify this compound to 264 
metabolites that are excreted. First, expression of CYP1A1/2, POR and cytochrome 265 
b5, the enzymes that all dictate metabolic activation and/or detoxification of ellipticine 266 
was analyzed. 267 
As shown in our previous study (Arlt et al. 2008), CYP1A1 and 1A2 enzymes 268 
are constitutively expressed in livers of untreated HRN and WT mice, with HRN mice 269 
having marginally higher levels (1.4-fold) than WT mice (Fig. 2). BaP was capable to 270 
effectively induce expression of both CYPs in livers of HRN and WT mice. Whereas 271 
exposure of these mice to BaP resulted in 8.9-fold higher levels of CYP1A1/2 in livers 272 
of WT mice, its inducing effect was higher in HRN mice; a 17.8-fold increase in 273 
CYP1A1/2 protein expression was caused by BaP in this mouse strain. The increase 274 
in CYP1A1/2 levels in the WT mice was associated with a strong increase in 275 
CYP1A1/2 marker activity, ethoxyresorufin O-demethylation (EROD) (Fig. 2C). 276 
Whereas CYP1A1/2 activity (EROD) was not detectable in untreated HRN mice, it 277 
was found in HRN mice treated with BaP. Its levels were, however, 3.4-fold lower 278 
than in WT mice treated with BaP. These findings are in concordance with previous 279 
studies, showing that expression of CYP1A1/2 is up-regulated by the aryl 280 
hydrocarbon receptor (AHR) and BaP can bind to and activate AHR, thereby 281 
enhancing metabolic activation of several genotoxic carcinogens, including BaP itself 282 
(Arlt et al. 2008; Hodek et al. 2011; Phillips & Venitt, 2012).  283 
The expression of POR was detected in liver of WT mice, while as expected, its 284 
expression in liver of HRN mice was very low, but still detectable by the Western 285 
  
 
 
blotting method (Fig. 2B). POR activity measured with cytochrome c as a substrate 286 
was, however, not detectable in hepatic microsomes of HRN mice (Fig. 2D). 287 
Surprisingly, the expression level of POR was also slightly induced in liver of both WT 288 
and HRN mice treated with BaP (Fig. 2B); a 1.2- and 1.4-fold increase in POR protein 289 
expression was mediated by treating the WT and HRN mice with BaP, respectively. 290 
Likewise, POR enzyme activity was detectable in hepatic microsomes from HRN 291 
mice treated with BaP (Fig. 2D).  292 
Interestingly, beside induction of expression of these enzymes by BaP, the 293 
levels of cytochrome b5 protein has also been found to be induced by treating both 294 
mouse strains with BaP; a 1.6- and 1.7-fold increase in cytochrome b5 protein levels 295 
was produced by BaP in livers of HRN and WT mice, respectively (Fig. 3) (Arlt et al. 296 
2012). 297 
Exposure of HRN and WT mice to BaP increases activation of ellipticine to form 298 
ellipticine-derived DNA adducts  299 
The activation of ellipticine by hepatic microsomes of HRN and WT mice was 300 
analyzed by the 32P-postlabeling technique (Fig. 4). In the presence of NADPH, a 301 
cofactor of POR- and CYP-dependent enzyme systems, the ex vivo incubations of 302 
hepatic microsomes of untreated (control) HRN and WT mice and mice treated with 303 
BaP with ellipticine and DNA led to activation of this drug to form ellipticine-derived 304 
DNA adducts (Fig. 4). The DNA adduct pattern generated by ellipticine consisted of 305 
at least two adducts (spots 1 and 2 in Figure 4), which were identical to those formed 306 
in vivo in mice and rats treated with ellipticine (Stiborova et al. 2003a, 2008), each 307 
formed by 13-hydroxyellipticine (Fig. 4C) or 12-hydroxyellipticine (Fig. 4D) 308 
metabolites that are generated by CYP and peroxidase (see Fig. 1). An additional 309 
  
 
 
ellipticine-derived DNA adduct, spot A, was found in DNA that had been incubated 310 
with ellipticine and mouse hepatic microsomes (Fig. 4A), predominantly in 311 
microsomes isolated from HRN mice (Table 1). This ellipticine-DNA adduct was not 312 
formed by either human or rat hepatic microsomes (Stiborova et al. 2001, 2003b, 313 
2004) or in mice (Fig. 4E and F) or rats in vivo (Stiborova et al. 2003a, 2007b, 2008). 314 
In incubations containing hepatic microsomes of HRN and WT mice treated with BaP, 315 
an additional adduct spot, corresponding to the 10-(deoxyguanosin-N2-yl)-7,8,9-316 
trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE) adduct that is the major 317 
product of reaction of BaP metabolite BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) with 318 
DNA in vitro and in vivo (Arlt et al. 2008; Phillips & Venitt, 2012) was also detected 319 
(Fig. 4B). This finding indicates that residual BaP is present in microsomes isolated 320 
from livers of HRN and WT mice, and is activated by CYP1A1 in combination with 321 
microsomal epoxide hydrolase (mEH) to form this adduct. Control incubations without 322 
microsomes were free of the dG-N2-BPDE adduct, ellipticine-DNA adducts 1 and A, 323 
but ellipticine-derived adduct 2 was always detected (data not shown). This finding is 324 
consistent with our previous results showing that this adduct is formed also non-325 
enzymatically (Stiborova et al. 2001, 2003b, 2004, 2007a). In the presence of 326 
microsomes without NADPH, beside ellipticine-DNA adducts 2, a low but detectable 327 
amount of the adduct 1 (Table 1) and the dG-N2-BPDE adduct was also found (data 328 
not shown).  329 
Surprisingly, levels of ellipticine-derived DNA adducts formed in ex vivo 330 
incubations of ellipticine and DNA with hepatic microsomes from HRN mice in the 331 
presence of NADPH were only 1.4-fold lower than amounts formed by hepatic 332 
microsomes from WT mice (Fig. 5 and Table 1), even though POR expression in 333 
  
 
 
livers of HRN mice was two orders of magnitude lower. This finding indicates that 334 
ellipticine activation should, at least partially, be catalyzed also by enzymes, whose 335 
activities are not dependent on POR (Stiborova et al. 2008). Beside peroxidases that 336 
were found to activate ellipticine (see Stiborova et al. 2007a and the results shown 337 
below), the CYP2S1 enzyme, which is abundantly expressed in several tissues 338 
(Downie et al. 2005; Saarikoski et al. 2005; Bui et al. 2009a) might be such an 339 
enzyme. Namely, it was shown that it catalyzes the oxidation of compounds having 340 
polycyclic aromatic structures similar to ellipticine without participation of POR (Bui et 341 
al. 2009a,b). Whereas a role of a COX peroxidase is investigated in this study, the 342 
participation of CYP2S1 in ellipticine activation still awaits further examination. 343 
Therefore, the efficiency of CYP2S1 to oxidize ellipticine is planned to be investigated 344 
in our future work. 345 
Treatment of both HRN and WT mice with BaP resulted in increased levels of 346 
ellipticine-derived DNA adducts formed in ex vivo incubations of ellipticine with 347 
hepatic microsomes of these mice relative to microsomes of untreated mice. A 2.2- 348 
and 10.4-fold increase in formation of amounts of ellipticine-derived DNA adducts 349 
was caused by exposure of HRN and WT mice to BaP, respectively, of them the 350 
levels of adduct 1 were predominantly increased. In contrast, a low (adduct 2 in both 351 
HRN and WT mice) or no increase (adduct A in HRN mice) in DNA adduct formation 352 
was produced by BaP (Table 1). 353 
Since CYP1A, 3A and peroxidase enzymes were found to activate ellipticine 354 
(Stiborova et al. 2001, 2003b, 2004, 2007a), we investigated the modulation of 355 
ellipticine-derived DNA adduct formation by cofactors and selective inhibitors of these 356 
  
 
 
enzymes using hepatic microsomes isolated from both untreated (control) mouse 357 
strains and the animals treated with BaP.  358 
α-Lipoic acid, a selective inhibitor of POR (Slepneva et al. 1995), decreased 359 
ellipticine-DNA adduct formation by 25-75% with mouse hepatic microsomes. 360 
Therefore, some activity in both HRN and WT mice is dependent on POR. α-NF, an 361 
inhibitor of CYP1A1 and 1A2 (Rendic & DiCarlo, 1997), decreased the levels of 362 
ellipticine-DNA adducts generated by hepatic microsomes of untreated HRN and WT 363 
mice as well as of WT mice treated with BaP, to essentially equal extent (to 40% in 364 
microsomes of WT and BaP-treated WT mice and to 50% in those of HRN mice), but 365 
had no inhibition effect of activation of ellipticine with microsomes of HRN mice 366 
treated with BaP (Fig. 5, Table 1). This finding proved a role of CYP1A in activation of 367 
WT and HRN mice, and mainly in WT mice in which CYP1A expression was induced 368 
with BaP. Induction of CYP1A in HRN mice resulted, however, in opposite process; 369 
induced CYP1A enzymes seem to increase ellipticine detoxification (see also below). 370 
Ketoconazole, a selective inhibitor of CYP3A enzymes (Rendic & DiCarlo, 1997; 371 
Ueng et al. 1997), inhibited formation of ellipticine-DNA adducts in hepatic 372 
microsomes of untreated (control) HRN and WT mice, by ~60%, but its effect was 373 
much lower in hepatic microsomes of BaP-treated HRN and WT mice, only by ~10% 374 
(Fig. 5, Table 1). These results point additionally to CYP3A enzymes as having a role 375 
in ellipticine-DNA adduct formation in mouse livers, but their contributions to this 376 
process was decreased by induction of CYP1A1 with BaP.   377 
Arachidonic acid, a cofactor for COX-dependent oxidation (Eling et al. 1990, 378 
1992; Stiborova et al. 2004, 2005; Arlt et al. 2006), mediated formation of DNA 379 
  
 
 
adducts 1 and 2 by ellipticine in hepatic microsomes of all mice used, but was much 380 
less effective than NADPH (Fig. 5, Table 1).  381 
Ellipticine metabolites formed in hepatic microsomes from all mouse strains used 382 
in this work were analogous; 9-hydroxy-, 12-hydroxy-, 13-hydroxy, 7-383 
hydroxyellipticine and N2-oxide of ellipticine were formed (Fig. 6). However, the 384 
amounts of individual metabolites in HRN and WT mice, either control (untreated) or 385 
treated with BaP, were different. In the case of untreated mice, 9-hydroxyellipticine 386 
levels were only one sixth, while the amounts of 13-hydroxy- and 12-387 
hydroxyellipticine, were about one half in incubations with HRN microsomes 388 
compared with the levels in incubations with WT microsomes. Exposure of both HRN 389 
and WT mouse strains to BaP resulted in an increase in formation of 9-hydroxy- and 390 
7-hydroxyellipticine, the metabolites that are considered to be detoxification products. 391 
More than 3- and 23-fold higher amounts of 9-hydroxy-and 7-hydroxyellipticine were 392 
formed by induction of CYP1A with BaP in WT mice, respectively. Likewise, 393 
treatment of HRN mice with BaP resulted in 3.8- and 5.5-fold higher levels of 9-394 
hydroxy-and 7-hydroxyellipticine generated by hepatic microsomes of these mice, 395 
respectively (Fig. 6). This result is consistent with findings of the former studies, 396 
where CYP1A1 and 1A2 were found to be the major enzymes forming these 397 
metabolites (Stiborova et al. 2004; Kotrbova et al. 2006, 2011). However, treatment 398 
of WT mice with BaP also resulted in up to 2.5-fold increased levels of 13-hydroxy- 399 
and 12-hydroxyellipticine (Fig. 6). Such an increase might result not only from 400 
induction of CYP1A enzymes by BaP, but also from induction of cytochrome b5 by 401 
this compound (see Fig. 3). Indeed, cytochrome b5 alters the ratio of ellipticine 402 
metabolites formed by CYP1A1 and 1A2 increasing the amounts of 13-hydroxy- and 403 
  
 
 
12-hydroxyellipticine (Kotrbova et al. 2011). The increased formation of both these 404 
ellipticine metabolites was associated with increased levels of ellipticine-DNA 405 
adducts that are generated by reaction of DNA with these two metabolites (see Figs. 406 
5, 6 and Table 1 and the results shown in Kotrbova et al. 2011 and Stiborova et al. 407 
2012b). In the case of HRN mice, no increase in 13-hydroxy- and 12-408 
hydroxyellipticine formation was found by treatment of these mice with BaP; a pattern 409 
of CYP1A1/2, POR and cytochrome b5 seems not to be appropriate to favor 410 
formation of these metabolites. Nevertheless, ellipticine-derived DNA adducts were 411 
increased when HRN mice were treated with BaP (Figs. 5, 6 and Table 1). There 412 
might be at least one reason for the above finding; activities of additional enzymes, 413 
beside CYPs, which are present in hepatic microsomes of HRN mice and are 414 
capable of activating ellipticine such as COX (Stiborova et al. 2007a) are induced by 415 
BaP. Indeed, an increase in formation of ellipticine-derived DNA adducts, 416 
predominantly the adduct 1, in ex vivo incubations of ellipticine with microsomes of 417 
HRN mice treated with BaP and arachidonic acid, a cofactor of COX, was found. 418 
Formation of adduct 1 from ellipticine13-ylium generated from COX-dependent 419 
formation of 6,13-didehydroellipticine (ellipticine mehylene-imine) (Fig. 1) should 420 
therefore also occur in hepatic microsomes of HRN mice treated with BaP. 421 
 422 
CONCLUSION 423 
Using mouse models in which expression of enzymes metabolizing ellipticine were 424 
modulated either by deletion in liver (POR) or by induction with BaP (CYP1A1/2 and 425 
cytochrome b5), we confirm a major role of CYP1A and 3A and participation of COX 426 
in ellipticine activation in these mice. Treatment of mice with BaP increases an 427 
  
 
 
impact of CYP1A on ellipticine activation. The results found also emphasize that a 428 
pattern of expression levels of these enzymes plays a crucial role in their impact on 429 
this process. Therefore, this study forms the basis to further predict the susceptibility 430 
of human cancers to ellipticine and suggests this alkaloid for treatment in 431 
combination with CYP gene transfer (Ma & Waxman, 2007; Lu et al. 2009) increasing 432 
the anticancer potential of this pro-drug.  433 
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Table 1. DNA adduct formation by ellipticine activated by hepatic microsomes from 637 
either untreated (control) Hepatic Cytochrome P450 Reductase Null (HRN) and 638 
wild-type (WT) mice (A) or mice treated with benzo[a]pyrene (BaP) (B)  639 
 640 
 641 
A RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot A   Total 
HRN mice hepatic 
microsomes + NADPH 
5.9±0.3 2.3±0.2 6.7±0.3   14.9±0.8 
HRN mice hepatic 
microsomes + NADPH + α-
lipoic acid 
1.2±0.1 1.7±0.1 0.9±0.1   3.8±0.3 
HRN mice hepatic 
microsomes + NADPH + α-
NF 
HRN mice hepatic 
microsomes + NADPH + 
ketoconazole 
HRN mice hepatic 
microsomes + arachidonic 
acid 
HRN mice hepatic 
microsomes without cofactor 
 
WT mice hepatic microsomes 
+ NADPH 
WT mice hepatic microsomes 
+ NADPH + α-lipoic acid 
WT mice hepatic microsomes 
+ NADPH + α-NF 
WT mice hepatic microsomes 
+ NADPH + ketoconazole 
WT mice hepatic microsomes 
+ arachidonic acid 
 
WT mice hepatic microsomes 
without cofactor 
2.8±0.2 
 
 
2.5±0.2 
 
 
2.9±0.2 
 
 
0.2±0.04 
 
 
13.0±0.9 
 
7.6±0.6 
 
6.5±0.5 
 
6.0±0.5 
 
5.7±0.4 
 
0.3±0.02 
 
2.2±0.2 
 
 
2.0±0.2 
 
 
2.4±0.2 
 
 
1.9±0.2 
 
 
3.2±0.2 
 
2.7±0.2 
 
2.7±0.2 
 
2.1±0.2 
 
4.6±0.3 
 
2.0±0.2 
 
1.0±0.1 
 
 
1.0±0.1 
 
 
  ND 
 
 
ND 
 
 
4.8±0.4 
 
0.7±0.1 
 
1.2±0.1 
 
1.0±0.1 
 
ND 
 
ND 
 
  6.0±0.5 
 
 
5.5±0.4 
 
 
5.3±0.4 
 
 
2.1±0.2 
 
 
21.0±1.5 
 
11.0±0.9 
 
10.4±0.8 
 
8.1±0.7 
 
10.3±0.8 
 
2.3±0.2 
 
 
642 
 
643 
 
644 
 
645 
 
646 
 
647 
  
 
 
 
648 
B RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot A   Total 
BaP-HRN mice hepatic 
microsomes + NADPH 
22.6±1.3 5.7±0.3 4.2±0.2   32.5±1.6 
BaP-HRN mice hepatic 
microsomes + NADPH + α-
lipoic acid 
21.5±1.0 3.4±0.2    ND 
 
  24.9±1.3 
BaP-HRN mice hepatic 
microsomes + NADPH + α-
NF 
BaP-HRN mice hepatic 
microsomes + NADPH + 
ketoconazole 
BaP-HRN mice hepatic 
microsomes + arachidonic 
acid 
BaP-HRN mice hepatic 
microsomes without cofactor 
 
BaP-WT mice hepatic 
microsomes + NADPH 
BaP-WT mice hepatic 
microsomes + NADPH + α-
lipoic acid 
BaP-WT mice hepatic 
microsomes + NADPH + α-
NF 
BaP-WT mice hepatic 
microsomes + NADPH + 
ketoconazole 
BaP-WT mice hepatic 
microsomes + arachidonic 
acid 
BaP-WT mice hepatic 
microsomes without cofactor 
30.6±1.5 
 
 
23.1±1.1 
 
 
10.1±0.5 
 
 
0.2±0.01 
 
 
181.7±6.3 
 
82.9±4.0 
 
 
83.5±4.1 
 
 
164.3±8.1 
 
 
8.1±0.4 
 
 
0.5±0.03 
 
6.7±0.3 
 
 
5.6±0.3 
 
 
2.3±0.1 
 
 
1.9±0.1 
 
 
8.3±0.4 
 
5.3±0.3 
 
 
4.1±0.2 
 
 
7.4±0.4 
 
 
2.6±0.1 
 
 
2.5±0.1 
 
ND  
 
 
ND  
 
 
   ND 
 
 
   ND 
 
 
28.7±1.2 
 
4.1±0.2 
 
 
3.8±0.2 
 
 
26.5±1.2 
 
 
ND 
 
 
ND 
 
  37.3±1.9 
 
 
28.7±1.4 
 
 
12.4±0.7 
 
 
2.1±0.1 
 
 
218.7±8.9 
 
92.3±4.4 
 
 
91.4±4.4 
 
 
198.2±9.1 
 
 
10.7±0.5 
 
 
3.0±0.1 
 
 
649 
a Mean RAL (relative adduct labeling) ± standard deviation (S.D.) of four 650 
determinations (duplicate analyses of two independent in vitro incubations). ND - not 651 
detected (the detection limit of RAL was 1/1010 nucleotides). For adduct spots 1,2 652 
and A, see Figure 4. NADPH - nicotinamidadeninedinucleotide phosphate (reduced); 653 
α-NF - α-naphthoflavone. 654 
  655 
 656 
  
 
 
Figure 1. Scheme of ellipticine metabolism by cytochrome P450 (CYP) enzymes 657 
showing the identified metabolites and those proposed to form DNA adducts. The 658 
compounds shown in brackets were not detected under the experimental conditions 659 
and/or not yet structurally characterized. The CYP enzymes predominantly oxidizing 660 
ellipticine shown in the figure were identified in our previous studies (Stiborova et al. 661 
2004, 2012b; Kotrbova et al. 2011). Reactions (rea) 1, 2 and 3 are reactions leading 662 
to ellipticine-13-ylium from 13-hydroxyellipticine, 13-hydroxyellipticine sulfate and 13-663 
hydroxyellipticine acetate, respectively.  664 
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Figure 2. Expression of cytochrome P450 (667 
P450 reductase (POR) (668 
deetylation (EROD) (C) and POR activity (669 
Reductase Null (HRN) and 670 
intraperitoneally (i.p.) with 125 mg 671 
days. Inset in A and B: immunoblots of microsomal CYP1A1/2 and POR from each 672 
mouse group, stained with antibody against rat CYP1A1 and rabbit POR, 673 
respectively. Pooled hepatic microsomal samples were used for analyses as 674 
described in Material and Methods. Values are given as means ± 675 
(S.D.) (n=3). Values significantly676 
ND= not detectable. AU - arbitrary units. 677 
(GAPDH) was used as loading control678 
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D)] in livers of Hepatic Cytochro
wild-type (WT) mice, control (untreated), or treated 
benzo[a]pyrene (BaP)/kg body weight daily for five 
standard deviations 
 different from untreated mice: *P<0.05, ***P<0.001. 
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 (adopted from Arlt et al. 2008)
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Figure 3. Expression of cytochrome b5 (cyt b5) in livers of Hepatic Cytochrome P450 708 
Reductase Null (HRN) and wild-type (WT) mice, control (untreated) mice or mice 709 
treated intraperitoneally (i.p.) with 125 mg/kg body weight (bw) benzo[a]pyrene (BaP) 710 
for 24 hours. Pooled hepatic microsomal samples (n=3) were used for analyses as 711 
described in Material and Methods. Values significantly different from untreated mice: 712 
***P<0.001. AU - arbitrary units. Glyceraldehyde phosphate dehydrogenase 713 
(GAPDH) was used as loading control (adopted from Arlt et al. 2012). 714 
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Figure 4. Autoradiographs of 750 
digests of calf thymus DNA reacted with ellipticine and hepatic microsomes from 751 
type (WT) mice (A), with those752 
mice treated with benzo[a]pyrene (753 
hydroxyellipticine (C) (Stiborova et al.754 
et al. 2007a) and of DNA from livers 755 
ellipticine/kg body weight (Stiborova et al.756 
nuclease P1 version of the 757 
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Figure 5. DNA adduct formation by ellipticine activated with microsomes isolated 781 
from livers of untreated Hepatic Cytochrome P450 Reductase Null (HRN) and wild-782 
type (WT) mice (A) and from those treated with BaP (B) as determined by thin layer 783 
chromatography (TLC) 32P-postlabeling. F = fold higher DNA adducts levels in 784 
microsomes from WT mice compared to HRN mice. Columns: Mean RAL (relative 785 
adduct labeling) ± standard deviations (S.D.) shown in the figure represent total 786 
levels of DNA adducts of four determinations (duplicate analyses of two independent 787 
in vitro incubations). Values significantly different from HRN mice:*P<0.05, **P<0.01, 788 
***P<0.001. Control = without cofactor; AA = arachidonic acid; α-NF = α-789 
naphthoflavone; α-LA = α-lipoic acid. ND = not detected. 790 
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Figure 6. Levels of ellipticine metabolites formed by hepatic microsomes (0.2 mg 815 
protein) of Hepatic Cytochrome P450 Reductase Null (HRN) and wild-type (WT) mice 816 
from 10 µM ellipticine and by hepatic microsomes of HRN and WT mice treated 817 
intraperitoneally (i.p.) with 5 × 125 mg of benzo[a]pyrene (BaP) per kg of body 818 
weight. Levels of ellipticine metabolites were determined by high performance liquid 819 
chromatography (HPLC) (Stiborova et al. 2004, 2006a) and are averages ± standard 820 
deviations of triplicate incubations. Values significantly different from untreated mice: 821 
*P<0.05, **P<0.01, ***P<0.001. 822 
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